Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...

with SARS-CoV-2 and CMV peptide pools increases the proportion of CD4⁺ and CD8⁺ T-Cells expressing exhaustion markers PD-1, LAG-3, TIGIT, TIM-3, and CD39 with each stimulation cycle.

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS ...

LAG-3 is a popular target, and following after is a clutch of drugs in mid-stage development, including Immutep's soluble LAG-3 protein eftilagimod alpha, Novartis/Immutep's leramilimab, Incyte's ...

The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.

The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...

Humans have been attempting to combat cancer since the time of the Ancient Egyptians, and recent decades have seen remarkable progress. However, tumor cells have developed sophisticated ways to evade ...